Biotech
-
445The 3CL Secret to Pfizer’s and Todos Medical’s Success
Pfizer’s (NYSE: PFE) PAXLOVID has risen to prominence as the top COVID-19 antiviral in the world. The speed at which they rose...
-
5521Picking a Bottom in CytoDyn – Right Now
CytoDyn Inc (OTCMKT: CYDY) has been under considerable selling pressure since April and nothing seems to be able to stop it. In...
-
1.7KAtea Failure Leaves Todos Medical (TOMDF) Last Man Standing in Oral Antivirals
The big news circulating this week was of Atea Pharmaceuticals’ (NASDAQ: AVIR) COVID-19 antiviral clinical trial failure, which instantly plummeted the stock...
-
3981Todos Medical (TOMDF) COVID-19 Oral Antiviral Takes Death off Table
Todos Medical (OTCMKTS: TOMDF) today announced excellent Phase 1/2 results that appear to take dying from COVID-19 off the table. In a...
-
355Stemcell Nutraceutical Leader ‘Stemtech’ Going Public via Merger with (OTCMKTS: GNTW) Globe Net Wireless Corp.
Glory Days Awaken the Sleeping Giant Globe Net Wireless Corp. (OTCMKTS: GNTW) isn’t your typical reverse merger deal because the acquiring asset...
-
528Moderna’s (MRNA) Bloated Market Cap & mRNA Vaccine Thesis Under Fire
Shares of Moderna (NASDAQ: MRNA) recently spiked over $400, giving the mRNA vaccine maker a market cap of about $200 billion, greater...
-
515CytoDyn (CYDY) Shorts Throttle Up Bashing Ahead of August Super News Cycle
Short attack timed to capitalize on consolidation and thin trading The Oregonian misquotes and twists statements taken out of context SEC case...
-
4782CytoDyn’s Preliminary Phase 1b/2 Cancer Results Likely to Receive Breakthrough Therapy Designation (BTD)
CytoDyn Inc. (OTCMKTS: CYDY) announced excellent preliminary results from its Phase 1b/2 clinical trial in metastatic triple negative breast cancer...
-
5701CytoDyn (CYDY) at Crossroads: Past and Current Leadership Collide in Epic Grudgematch
Latest 8-K filing settles dispute for $7.6 million but paves way for Pestell share repurchase at par 13-D Group is outspoken but...
-
563Enzolytics (ENZC) Takes on HIV Heavyweight Gilead Sciences
The cocktail of drugs given to HIV patients has been dominated by Gilead Sciences (GILD) for over a decade. They are the...